Table 1 Average Score and Number of Cystadenomas per Kidney for A/J and C57BL/6 Tsc2+/- Cohorts
Tsc2+/-Cohort (strain, treatment, age) | Score per Kidney (ave ± std dev) | Number per Kidney (ave ± std dev) | % Reduction in Score per Kidney vs. Group 4 | n | Group Number | Number of Rapa Doses | Duration of Treatment | Total Dose per Mouse (mg) |
|---|---|---|---|---|---|---|---|---|
C57BL/6, untreated, 12 months | 15.19 ± 9.39 | 5.94 ± 2.79 |  | 8 |  |  |  |  |
A/J, untreated, 3 months | 6.50 ± 4.60 | 4.00 ± 1.69 |  | 4 |  |  |  |  |
A/J, untreated, 5 months | 33.00 ± 13.53 | 13.00 ± 4.28 |  | 4 |  |  |  |  |
A/J, untreated, 7 months | 57.75 ± 18.24 | 22.50 ± 5.88 |  | 4 |  |  |  |  |
A/J, untreated, 9 months | 74.47 ± 23.07 | 22.63 ± 6.66 |  | 16 |  |  |  |  |
**A/J, untreated, 12 months | 120.20 ± 52.53 | 35.25 ± 14.22 |  | 8 | 4 |  |  |  |
Group 1 *A/J rapa daily × 4 weeks then weekly × 8 weeks | 21.50 ± 8.38 | 7.38 ± 2.83 | 82% | 8 | 1 | 28 | 12 weeks | 6.72 |
Group 2 *A/J rapa daily × 4 weeks | 41.13 ± 25.33 | 13.25 ± 6.32 | 66% | 8 | 2 | 20 | 4 weeks | 4.8 |
Group 3 *A/J rapa weekly × 12 weeks | 22.61 ± 9.89 | 8.17 ± 3.07 | 81% | 9 | 3 | 12 | 12 weeks | 2.88 |